WallStreetZenWallStreetZen

NASDAQ: KNSA
Kiniksa Pharmaceuticals International PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KNSA

Based on 4 analysts offering 12 month price targets for Kiniksa Pharmaceuticals International PLC

Min Forecast
$34.00+0.74%
Avg Forecast
$42.50+25.93%
Max Forecast
$54.00+60%

Should I buy or sell KNSA stock?

Based on 4 analysts offering ratings for Kiniksa Pharmaceuticals International PLC.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their KNSA stock forecasts and price targets.

KNSA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-29
lockedlocked$00.00+00.00%2025-07-09
lockedlocked$00.00+00.00%2025-04-16
lockedlocked$00.00+00.00%2025-03-13

1 of 1

Forecast return on equity

Is KNSA forecast to generate an efficient return?

Company
42.44%
Industry
124.07%
Market
-49.12%
KNSA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KNSA forecast to generate an efficient return on assets?

Company
31.78%
Industry
47.18%
KNSA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KNSA earnings per share forecast

What is KNSA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.03+1,616.67%
Avg 2 year Forecast
$1.60+2,572.17%
Avg 3 year Forecast
$2.13+3,450%
KNSA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

KNSA revenue forecast

What is KNSA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$638.6M+20.64%
Avg 2 year Forecast
$798.4M+50.84%
Avg 3 year Forecast
$935.7M+76.76%
KNSA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KNSA earnings growth forecast

How is KNSA forecast to perform vs Biotechnology companies and vs the US market?

Company
229.06%
Industry
5.33%
Market
15.31%
KNSA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
KNSA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
KNSA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

KNSA revenue growth forecast

How is KNSA forecast to perform vs Biotechnology companies and vs the US market?

Company
21.07%
Industry
78.36%
Market
10.83%
KNSA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KNSA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KNSA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KNSA$33.75$42.50+25.93%Strong Buy
VCYT$31.00$42.00+35.48%Strong Buy
CPRX$21.08$33.33+58.13%Strong Buy
TARS$57.25$66.33+15.87%Strong Buy
FOLD$7.61$46.33+508.84%Strong Buy
View Top Biotech Stocks

Kiniksa Pharmaceuticals International Stock Forecast FAQ

Is Kiniksa Pharmaceuticals International Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: KNSA) stock is to Strong Buy KNSA stock.

Out of 4 analysts, 3 (75%) are recommending KNSA as a Strong Buy, 1 (25%) are recommending KNSA as a Buy, 0 (0%) are recommending KNSA as a Hold, 0 (0%) are recommending KNSA as a Sell, and 0 (0%) are recommending KNSA as a Strong Sell.

If you're new to stock investing, here's how to buy Kiniksa Pharmaceuticals International stock.

What is KNSA's earnings growth forecast for 2025-2027?

(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's forecast annual earnings growth rate of 229.06% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.33%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Kiniksa Pharmaceuticals International's earnings in 2025 is $4,790,000.On average, 3 Wall Street analysts forecast KNSA's earnings for 2025 to be $76,330,898, with the lowest KNSA earnings forecast at $63,732,594, and the highest KNSA earnings forecast at $94,116,738. On average, 3 Wall Street analysts forecast KNSA's earnings for 2026 to be $118,816,824, with the lowest KNSA earnings forecast at $82,259,511, and the highest KNSA earnings forecast at $173,411,943.

In 2027, KNSA is forecast to generate $157,849,333 in earnings, with the lowest earnings forecast at $103,009,659 and the highest earnings forecast at $233,439,154.

What is KNSA's revenue growth forecast for 2025-2027?

(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's forecast annual revenue growth rate of 21.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Kiniksa Pharmaceuticals International's revenue in 2025 is $529,332,000.On average, 3 Wall Street analysts forecast KNSA's revenue for 2025 to be $47,325,897,861, with the lowest KNSA revenue forecast at $46,910,153,844, and the highest KNSA revenue forecast at $47,829,088,927. On average, 3 Wall Street analysts forecast KNSA's revenue for 2026 to be $59,170,230,007, with the lowest KNSA revenue forecast at $56,627,151,272, and the highest KNSA revenue forecast at $62,294,164,644.

In 2027, KNSA is forecast to generate $69,339,802,964 in revenue, with the lowest revenue forecast at $63,039,687,784 and the highest revenue forecast at $76,148,593,177.

What is KNSA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KNSA) forecast ROA is 31.78%, which is lower than the forecast US Biotechnology industry average of 47.18%.

What is KNSA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year KNSA price target, the average KNSA price target is $42.50, with the highest KNSA stock price forecast at $54.00 and the lowest KNSA stock price forecast at $34.00.

On average, Wall Street analysts predict that Kiniksa Pharmaceuticals International's share price could reach $42.50 by Jul 29, 2026. The average Kiniksa Pharmaceuticals International stock price prediction forecasts a potential upside of 25.93% from the current KNSA share price of $33.75.

What is KNSA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's current Earnings Per Share (EPS) is $0.06. On average, analysts forecast that KNSA's EPS will be $1.03 for 2025, with the lowest EPS forecast at $0.86, and the highest EPS forecast at $1.27. On average, analysts forecast that KNSA's EPS will be $1.60 for 2026, with the lowest EPS forecast at $1.11, and the highest EPS forecast at $2.34. In 2027, KNSA's EPS is forecast to hit $2.13 (min: $1.39, max: $3.15).

What is KNSA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KNSA) forecast ROE is 42.44%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.